
    
      PATIENT POPULATION Resected pancreatic cancer patients (R0 resection) within 10 weeks of
      surgery will be eligible, provided that they meet standard eligibility criteria.

      STUDY DESIGN Phase II, open-label trial of erlotinib and gemcitabine. SAFETY PLAN Safety as
      assessed by CTCAE 3.0 STUDY TREATMENT Erlotinib 150 mg/day x 12 months. (oral) Gemcitabine
      1500 mg/m2 IV over 150 minutes q 2 weeks x 4 months Patients will be monitored with serial CT
      scans for the first 2 years after completion of therapy.

      Clinical Practice: Therapy will be administered as an outpatient. Primary Evaluations: Time
      to recurrence CONCOMITANT THERAPY AND CLINICAL PRACTICE No other anti-cancer therapy will be
      allowed while on study.
    
  